Nanotechnology as a potential therapeutic alternative for schistosomiasis

Acta Trop. 2017 Oct:174:64-71. doi: 10.1016/j.actatropica.2017.06.025. Epub 2017 Jun 29.

Abstract

Schistosomiasis is a neglected disease that affects millions of people worldwide, recognized as the most important human helminth infection in terms of morbidity and mortality. The treatment of choice presents low bioavailability and water solubility, in addition to the induction of parasite resistance. In this context, researchers have been conducting studies seeking to develop new drugs to ensure safety, quality, and efficacy against this parasitosis. In this scenario, nanotechnology arises including the drug delivery systems in nanoscale: nanoemulsions, liposomes and nanoparticles. These drug delivery systems have been extensively applied for in vitro and in vivo studies against Schistosoma spp. with promising results. This review pointed out the most relevant development scenarios regarding the treatment of schistosomiasis as well as the application of nanotechnology as a vaccine, highlighting the use of nanotechnology as an alternative therapy for both the repositioning of drugs and the use of new pharmaceutical products, with promising results regarding the aforementioned disease.

Keywords: Drug delivery systems; Liposome; Nanocapsule; Nanoemulsion; Nanoparticle; Nanosphere.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Delivery Systems*
  • Humans
  • Nanotechnology*
  • Protozoan Vaccines / administration & dosage
  • Protozoan Vaccines / immunology*
  • Schistosomiasis / drug therapy*
  • Schistosomiasis / prevention & control
  • Schistosomicides / administration & dosage
  • Schistosomicides / chemistry
  • Schistosomicides / therapeutic use*

Substances

  • Protozoan Vaccines
  • Schistosomicides